Bioventus (NASDAQ:BVS) Updates FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus estimate of 0.770. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $605.1 million.

Bioventus Trading Up 12.0%

Shares of BVS traded up $1.61 during trading hours on Wednesday, hitting $15.03. The company had a trading volume of 1,980,991 shares, compared to its average volume of 519,203. Bioventus has a 52-week low of $6.26 and a 52-week high of $15.89. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The stock’s 50 day moving average price is $10.47 and its 200 day moving average price is $9.56. The firm has a market cap of $1.26 billion, a P/E ratio of 36.82, a P/E/G ratio of 1.72 and a beta of 0.63.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts predict that Bioventus will post 0.79 EPS for the current year.

Analyst Ratings Changes

BVS has been the subject of a number of recent analyst reports. Barrington Research reiterated an “outperform” rating and set a $14.00 price target on shares of Bioventus in a report on Tuesday, June 30th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research report on Tuesday, June 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $14.75.

Institutional Trading of Bioventus

Large investors have recently bought and sold shares of the company. Prelude Capital Management LLC bought a new position in shares of Bioventus in the 3rd quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus in the third quarter worth $78,000. Brooklyn Investment Group purchased a new stake in Bioventus in the fourth quarter worth $91,000. O Shaughnessy Asset Management LLC bought a new position in Bioventus in the fourth quarter worth $99,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in Bioventus during the third quarter valued at $96,000. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.